Literature DB >> 33615670

Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET.

Margarita Raygada1, Mark Raffeld2, Andrew Bernstein3, Markku Miettinen2, John Glod1, Marybeth S Hughes4, Karlyne Reilly1, Brigitte Widemann1, Jaydira Del Rivero5.   

Abstract

Adrenocortical carcinoma (ACC) is a rare aggressive malignancy that originates in the outer layer of the adrenal gland. Most ACCs are sporadic, but a small percentage of cases are due to hereditary cancer syndromes such as Li-Fraumeni syndrome (LFS), Lynch syndrome (LS), and familial adenomatous polyposis (FAP). Multiple endocrine neoplasia type 2A (MEN2A) is an inherited disorder that predisposes to medullary thyroid cancer, pheochromocytoma, and parathyroid hyperplasia. We present here a case of ACC with both LS and MEN2A; the family and medical history were consistent with Lynch. This is, to our knowledge, the first report of a patient with ACC associated with germline mutations in RET and MSH2, and no phenotypical characteristics of MEN2A.
© 2021 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals LLC.

Entities:  

Keywords:  Lynch syndrome; adrenocortical cancer; multiple endocrine neoplasia type 2A

Mesh:

Substances:

Year:  2021        PMID: 33615670      PMCID: PMC7986073          DOI: 10.1002/ajmg.a.62099

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  31 in total

1.  Loss of heterozygosity at the RET protooncogene locus in a case of multiple endocrine neoplasia type 2A.

Authors:  L Quadro; O Fattoruso; M P Cosma; U Verga; A Porcellini; A Libroia; V Colantuoni
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

Review 2.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

3.  Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.

Authors:  G L Feldman; M W Edmonds; P J Ainsworth; I Schuffenecker; G M Lenoir; A W Saxe; G B Talpos; J Roberson; N Petrucelli; C E Jackson
Journal:  Surgery       Date:  2000-07       Impact factor: 3.982

4.  Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.

Authors:  Bryce A Seifert; Julianne M O'Daniel; Krunal Amin; Daniel S Marchuk; Nirali M Patel; Joel S Parker; Alan P Hoyle; Lisle E Mose; Andrew Marron; Michele C Hayward; Christopher Bizon; Kirk C Wilhelmsen; James P Evans; H Shelton Earp; Norman E Sharpless; D Neil Hayes; Jonathan S Berg
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

Review 5.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

6.  Adrenocortical carcinoma is a lynch syndrome-associated cancer.

Authors:  Victoria M Raymond; Jessica N Everett; Larissa V Furtado; Shanna L Gustafson; Chelsy R Jungbluth; Stephen B Gruber; Gary D Hammer; Elena M Stoffel; Joel K Greenson; Thomas J Giordano; Tobias Else
Journal:  J Clin Oncol       Date:  2013-07-22       Impact factor: 44.544

Review 7.  Medullary thyroid cancer: management guidelines of the American Thyroid Association.

Authors:  Richard T Kloos; Charis Eng; Douglas B Evans; Gary L Francis; Robert F Gagel; Hossein Gharib; Jeffrey F Moley; Furio Pacini; Matthew D Ringel; Martin Schlumberger; Samuel A Wells
Journal:  Thyroid       Date:  2009-06       Impact factor: 6.568

8.  Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.

Authors:  Berna İmge Aydoğan; Bağdagül Yüksel; Mazhar Müslüm Tuna; Mehtap Navdar Başaran; Ayşen Akkurt Kocaeli; Melek Eda Ertörer; Kadriye Aydın; Sibel Güldiken; Yasin Şimşek; Züleyha Cihan Karaca; Merve Yılmaz; Müjde Aktürk; İnan Anaforoğlu; Nur Kebapçı; Cevdet Duran; Abdullah Taşlıpınar; Mustafa Kulaksızoğlu; Alptekin Gürsoy; Selçuk Dağdelen; Murat Faik Erdoğan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-12-18

9.  p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer.

Authors:  Chey Loveday; Katherine Josephs; Daniel Chubb; Adam Gunning; Louise Izatt; Marc Tischkowitz; Sian Ellard; Clare Turnbull
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 10.  The genetic basis of Lynch syndrome and its implications for clinical practice and risk management.

Authors:  Stephanie A Cohen; Anna Leininger
Journal:  Appl Clin Genet       Date:  2014-07-22
View more
  1 in total

1.  Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET.

Authors:  Margarita Raygada; Mark Raffeld; Andrew Bernstein; Markku Miettinen; John Glod; Marybeth S Hughes; Karlyne Reilly; Brigitte Widemann; Jaydira Del Rivero
Journal:  Am J Med Genet A       Date:  2021-02-21       Impact factor: 2.802

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.